Pneumocystis jirovecii Pneumonia in Human Immunodeficiency Virus Infection

Abstract

The presentation of Pneumocystis pneumonia (PCP) in previously healthy men having sex with men (MSM) in San Francisco and New York City in 1981 heralded the beginning of the human immunodeficiency virus (HIV) pandemic. Despite a decreasing incidence of PCP among patients with HIV/AIDS (acquired immunodeficiency syndrome) since the advent of combination antiretroviral therapy in the mid-1990s, PCP remains one of the most common AIDS-defining opportunistic infections in the United States and Western Europe. Newer molecular diagnostic tests in conjunction with standard immunofluorescent or colorimetric tests have allowed for more rapid and accurate diagnosis. Although several effective oral and intravenous therapies exist to treat PCP, mortality rates in HIV-infected individuals remain unacceptably high, especially in those with advanced AIDS. The identification of specific mutations in Pneumocystis genes targeted by trimethoprim–sulfamethoxazole has raised concerns about the development of resistance to the drug of choice and may ultimately lead to greater utilization of alternative therapies to treat PCP in the future.

Keywords

Pneumocystis jirovecii - pneumonia - acquired immunodeficiency syndrome - human immunodeficiency virus - trimethoprim–sulfamethoxazole

• References

• 1 Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009; 301 (24) 2578-2585
• 2 Walzer PD, Perl DP, Krogstad DJ, Rawson PG, Schultz MG. Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features. Ann Intern Med 1974; 80 (1) 83-93
• 3 Centers for Disease Control (CDC). Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30 (25) 305-308
• 4 Gottlieb MS. Pneumocystis pneumonia—Los Angeles. 1981. Am J Public Health 2006; 96 (6) 980-981 , discussion 982–983
• 5 Llibre JM, Revollo B, Vanegas S , et al. Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries. Scand J Infect Dis 2013; 45 (8) 635-644
• 6 Lee SH, Kim KH, Lee SG , et al. Trends of mortality and cause of death among HIV-infected patients in Korea, 1990-2011. J Korean Med Sci 2013; 28 (1) 67-73
• 7 Fei MW, Sant CA, Kim EJ , et al. Severity and outcomes of Pneumocystis pneumonia in patients newly diagnosed with HIV infection: an observational cohort study. Scand J Infect Dis 2009; 41 (9) 672-678
• 8 Radhi S, Alexander T, Ukwu M, Saleh S, Morris A. Outcome of HIV-associated Pneumocystis pneumonia in hospitalized patients from 2000 through 2003. BMC Infect Dis 2008; 8: 118
• 9 Kovacs JA, Hiemenz JW, Macher AM , et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984; 100 (5) 663-671
• 10 Fei MW, Kim EJ, Sant CA , et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009; 64 (12) 1070-1076
• 11 Walzer PD, Evans HE, Copas AJ, Edwards SG, Grant AD, Miller RF. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008; 46 (4) 625-633
• 12 Fisk M, Sage EK, Edwards SG, Cartledge JD, Miller RF. Outcome from treatment of Pneumocystis jirovecii pneumonia with co-trimoxazole. Int J STD AIDS 2009; 20 (9) 652-653
• 13 Roux A, Canet E, Valade S , et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014; 20 (9) 1490-1497
• 14 Gigliotti F, Haidaris PJ, Haidaris CG, Wright TW, Van der Meid KR. Further evidence of host species-specific variation in antigens of Pneumocystis carinii using the polymerase chain reaction. J Infect Dis 1993; 168 (1) 191-194
• 15 Gigliotti F, Harmsen AG, Haidaris CG, Haidaris PJ. Pneumocystis carinii is not universally transmissible between mammalian species. Infect Immun 1993; 61 (7) 2886-2890
• 16 Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8 (9) 891-896
• 17 Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334 (6182) 519-522
• 18 Ma L, Huang DW, Cuomo CA , et al. Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis . FASEB J 2013; 27 (5) 1962-1972
• 19 Krajicek BJ, Thomas Jr CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med 2009; 30 (2) 265-278 , vi
• 20 Thomas Jr CF, Limper AH. Pneumocystis pneumonia . N Engl J Med 2004; 350 (24) 2487-2498
• 21 Connor DH , ed. Pathology of Infectious Diseases. 1st ed. Stamford, CT: McGraw-Hill Professional; 1997
• 22 Bartlett MS, Queener SF, Shaw MM, Richardson JD, Smith JW. Pneumocystis carinii is resistant to imidazole antifungal agents. Antimicrob Agents Chemother 1994; 38 (8) 1859-1861
• 23 Vassallo R, Standing JE, Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000; 164 (7) 3755-3763
• 24 Morris A, Beard CB, Huang L. Update on the epidemiology and transmission of Pneumocystis carinii . Microbes Infect 2002; 4 (1) 95-103
• 25 Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii . J Infect Dis 1982; 145 (6) 842-848
• 26 Gianella S, Haeberli L, Joos B , et al. Molecular evidence of interhuman transmission in an outbreak of Pneumocystis jirovecii pneumonia among renal transplant recipients. Transpl Infect Dis 2010; 12 (1) 1-10
• 27 Olsson M, Lidman C, Latouche S , et al. Identification of Pneumocystis carinii f. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998; 36 (6) 1737-1740
• 28 Spencer L, Ukwu M, Alexander T , et al. Epidemiology of Pneumocystis colonization in families. Clin Infect Dis 2008; 46 (8) 1237-1240
• 29 Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008; 197 (1) 10-17
• 30 Ponce CA, Gallo M, Bustamante R, Vargas SL. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010; 50 (3) 347-353
• 31 Beard CB, Carter JL, Keely SP , et al. Genetic variation in Pneumocystis carinii isolates from different geographic regions: implications for transmission. Emerg Infect Dis 2000; 6 (3) 265-272
• 32 Beard CB, Fox MR, Lawrence GG , et al. Genetic differences in Pneumocystis isolates recovered from immunocompetent infants and from adults with AIDS: epidemiological implications. J Infect Dis 2005; 192 (10) 1815-1818
• 33 Vargas SL, Hughes WT, Santolaya ME , et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001; 32 (6) 855-861
• 34 Larsen HH, von Linstow ML, Lundgren B, Høgh B, Westh H, Lundgren JD. Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 2007; 13 (1) 66-72
• 35 Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MF. Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993; 270 (4) 470-473
• 36 Kovacs JA, Halpern JL, Swan JC, Moss J, Parrillo JE, Masur H. Identification of antigens and antibodies specific for Pneumocystis carinii . J Immunol 1988; 140 (6) 2023-2031
• 37 Davis JL, Welsh DA, Beard CB , et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia . Thorax 2008; 63 (4) 329-334
• 38 Huang L, Beard CB, Creasman J , et al. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J Infect Dis 2000; 182 (4) 1192-1198
• 39 Keely SP, Baughman RP, Smulian AG, Dohn MN, Stringer JR. Source of Pneumocystis carinii in recurrent episodes of pneumonia in AIDS patients. AIDS 1996; 10 (8) 881-888
• 40 Keely SP, Stringer JR. Multi-locus genotype switching in Pneumocystis carinii sp. f. hominis: evidence for reinfection. J Eukaryot Microbiol 1996; 43 (5) 50S
• 41 Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian AG. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 1995; 172 (2) 595-598
• 42 Morris A, Lundgren JD, Masur H , et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10 (10) 1713-1720
• 43 Fisk DT, Meshnick S, Kazanjian PH. Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin Infect Dis 2003; 36 (1) 70-78
• 44 Phair J, Muñoz A, Detels R, Kaslow R, Rinaldo C, Saah A ; Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322 (3) 161-165
• 45 Stansell JD, Osmond DH, Charlebois E , et al; Pulmonary Complications of HIV Infection Study Group. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Am J Respir Crit Care Med 1997; 155 (1) 60-66
• 46 Buchacz K, Baker RK, Palella Jr FJ , et al; HOPS Investigators. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010; 24 (10) 1549-1559
• 47 Mocroft A, Sterne JA, Egger M , et al; Antiretroviral Therapy Cohort Collaboration (ART-CC). Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48 (8) 1138-1151
• 48 Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178 (4) 1126-1132
• 49 Mocroft A, Reiss P, Kirk O , et al; Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis 2010; 51 (5) 611-619
• 50 Gilroy SA, Bennett NJ. Pneumocystis pneumonia . Semin Respir Crit Care Med 2011; 32 (6) 775-782
• 51 Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 10 (3) 401-418
• 52 Raviglione MC. Extrapulmonary pneumocystosis: the first 50 cases. Rev Infect Dis 1990; 12 (6) 1127-1138
• 53 Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 1998; 113 (5) 1225-1229
• 54 Cohen OJ, Stoeckle MY. Extrapulmonary Pneumocystis carinii infections in the acquired immunodeficiency syndrome. Arch Intern Med 1991; 151 (6) 1205-1214
• 55 Ewig S, Schäfer H, Rockstroh JK, Pickenhain A, Lüderitz B. Effect of long-term primary aerosolized pentamidine prophylaxis on breakthrough Pneumocystis carinii pneumonia. Eur Respir J 1996; 9 (5) 1006-1012
• 56 Rubin EFJ , ed. Pathology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1994
• 57 Tasaka S, Hasegawa N, Kobayashi S , et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest 2007; 131 (4) 1173-1180
• 58 Quist J, Hill AR. Serum lactate dehydrogenase (LDH) in Pneumocystis carinii pneumonia, tuberculosis, and bacterial pneumonia. Chest 1995; 108 (2) 415-418
• 59 Esteves F, Lee CH, de Sousa B , et al. (1-3)-beta-D-glucan in association with lactate dehydrogenase as biomarkers of Pneumocystis pneumonia (PcP) in HIV-infected patients. Eur J Clin Microbiol Infect Dis 2014; 33 (7) 1173-1180
• 60 Sax PE, Komarow L, Finkelman MA , et al; AIDS Clinical Trials Group Study A5164 Team. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011; 53 (2) 197-202
• 61 Tasaka S, Kobayashi S, Yagi K , et al. Serum (1 → 3) β-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother 2014; 20 (11) 678-681
• 62 Crans Jr CA, Boiselle PM. Imaging features of Pneumocystis carinii pneumonia. Crit Rev Diagn Imaging 1999; 40 (4) 251-284
• 63 DeLorenzo LJ, Huang CT, Maguire GP, Stone DJ. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987; 91 (3) 323-327
• 64 Chow C, Templeton PA, White CS. Lung cysts associated with Pneumocystis carinii pneumonia: radiographic characteristics, natural history, and complications. AJR Am J Roentgenol 1993; 161 (3) 527-531
• 65 Gruden JF, Huang L, Turner J , et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997; 169 (4) 967-975
• 66 Opravil M, Marincek B, Fuchs WA , et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1994; 7 (1) 39-45
• 67 Kanne JP, Yandow DR, Meyer CA. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 2012; 198 (6) W555-61
• 68 Fujii T, Nakamura T, Iwamoto A. Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features. J Infect Chemother 2007; 13 (1) 1-7
• 69 Boiselle PM, Crans Jr CA, Kaplan MA. The changing face of Pneumocystis carinii pneumonia in AIDS patients. AJR Am J Roentgenol 1999; 172 (5) 1301-1309
• 70 Hardak E, Brook O, Yigla M. Radiological features of Pneumocystis jirovecii Pneumonia in immunocompromised patients with and without AIDS. Lung 2010; 188 (2) 159-163
• 71 Richards PJ, Riddell L, Reznek RH, Armstrong P, Pinching AJ, Parkin JM. High resolution computed tomography in HIV patients with suspected Pneumocystis carinii pneumonia and a normal chest radiograph. Clin Radiol 1996; 51 (10) 689-693
• 72 Datta D, Ali SA, Henken EM, Kellet H, Brown S, Metersky ML. Pneumocystis carinii pneumonia: the time course of clinical and radiographic improvement. Chest 2003; 124 (5) 1820-1823
• 73 Turner D, Schwarz Y, Yust I. Induced sputum for diagnosing Pneumocystis carinii pneumonia in HIV patients: new data, new issues. Eur Respir J 2003; 21 (2) 204-208
• 74 Huang L, Hecht FM, Stansell JD, Montanti R, Hadley WK, Hopewell PC. Suspected Pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful?. Am J Respir Crit Care Med 1995; 151 (6) 1866-1871
• 75 Silva RM, Bazzo ML, Borges AA. Induced sputum versus bronchoalveolar lavage in the diagnosis of pneumocystis jiroveci pneumonia in human immunodeficiency virus-positive patients. Braz J Infect Dis 2007; 11 (6) 549-553
• 76 Cruciani M, Marcati P, Malena M, Bosco O, Serpelloni G, Mengoli C. Meta-analysis of diagnostic procedures for Pneumocystis carinii pneumonia in HIV-1-infected patients. Eur Respir J 2002; 20 (4) 982-989
• 77 Narasimha PD, Prabha MR, Harsha AB, Thomas RJ, Shenoy S, Chakrapani M. Role of multiple induced sputum examination in the diagnosis of Pneumocystis carinii pneumonia. Southeast Asian J Trop Med Public Health 2004; 35 (3) 702-704
• 78 Saksirisampant W, Eampokalap B, Chantharodevong R, Changthong R. Comparison of methods for identification of Pneumocystis carinii in bronchoalveolar lavage fluid. J Med Assoc Thai 2002; 85 (Suppl. 01) S407-S414
• 79 Kovacs JA, Ng VL, Masur H , et al. Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med 1988; 318 (10) 589-593
• 80 Procop GW, Haddad S, Quinn J , et al. Detection of Pneumocystis jiroveci in respiratory specimens by four staining methods. J Clin Microbiol 2004; 42 (7) 3333-3335
• 81 Carmona EM, Limper AH. Update on the diagnosis and treatment of Pneumocystis pneumonia . Ther Adv Respir Dis 2011; 5 (1) 41-59
• 82 Huggett JF, Taylor MS, Kocjan G , et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008; 63 (2) 154-159
• 83 Oren I, Hardak E, Finkelstein R, Yigla M, Sprecher H. Polymerase chain reaction-based detection of Pneumocystis jirovecii in bronchoalveolar lavage fluid for the diagnosis of pneumocystis pneumonia. Am J Med Sci 2011; 342 (3) 182-185
• 84 Lu Y, Ling G, Qiang C , et al. PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol 2011; 49 (12) 4361-4363
• 85 Alvarez-Martínez MJ, Miró JM, Valls ME , et al; Spanish PCP Working Group. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis 2006; 56 (2) 153-160
• 86 Damiani C, Le Gal S, Da Costa C, Virmaux M, Nevez G, Totet A. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization. J Clin Microbiol 2013; 51 (10) 3380-3388
• 87 Larsen HH, Huang L, Kovacs JA , et al. A prospective, blinded study of quantitative touch-down polymerase chain reaction using oral-wash samples for diagnosis of Pneumocystis pneumonia in HIV-infected patients. J Infect Dis 2004; 189 (9) 1679-1683
• 88 Caliendo AM, Hewitt PL, Allega JM, Keen A, Ruoff KL, Ferraro MJ. Performance of a PCR assay for detection of Pneumocystis carinii from respiratory specimens. J Clin Microbiol 1998; 36 (4) 979-982
• 89 Castro JG, Morrison-Bryant M. Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions. HIV AIDS (Auckl) 2010; 2: 123-134
• 90 Helweg-Larsen J, Benfield T, Atzori C, Miller RF. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study. J Antimicrob Chemother 2009; 64 (6) 1282-1290
• 91 Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H ; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58 (RR-4): 1-207 , quiz CE1–CE4
• 92 Miller RF, Huang L, Walzer PD. Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med 2013; 34 (2) 229-241
• 93 Thoden J, Potthoff A, Bogner JR , et al; Deutsche AIDS Gesellschaft; Österreichische AIDS-Gesellschaft. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection 2013; 41 (Suppl. 02) S91-S115
• 94 Dilworth TJ, Ibrahim OM, Mercier RC. Impact of an intravenous trimethoprim/sulfamethoxazole shortage on treatment outcomes among HIV-infected patients with Pneumocystis jirovecii pneumonia. J Manag Care Spec Pharm 2014; 20 (12) 1246-1254
• 95 Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1983; 2 (8359) 1109-1111
• 96 Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100 (4) 495-499
• 97 Wharton JM, Coleman DL, Wofsy CB , et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986; 105 (1) 37-44
• 98 Safrin S, Finkelstein DM, Feinberg J , et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124 (9) 792-802
• 99 Hughes WT, LaFon SW, Scott JD, Masur H. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J Infect Dis 1995; 171 (5) 1295-1301
• 100 Medina I, Mills J, Leoung G , et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323 (12) 776-782
• 101 Temesgen Z, Beri G. HIV and drug allergy. Immunol Allergy Clin North Am 2004; 24 (3) 521-531 , viii
• 102 Taqi SA, Zaki SA, Nilofer AR, Sami LB. Trimethoprim-sulfamethoxazole-induced Steven Johnson syndrome in an HIV-infected patient. Indian J Pharmacol 2012; 44 (4) 533-535
• 103 Langlois MR, Derk F, Belczyk R, Zgonis T. Trimethoprim-sulfamethoxazole-induced Stevens-Johnson syndrome: a case report. J Am Podiatr Med Assoc 2010; 100 (4) 299-303
• 104 Yang JJ, Huang CH, Liu CE , et al. Multicenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumonia. PLoS ONE 2014; 9 (9) e106141
• 105 Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis 1994; 170 (4) 912-917
• 106 Fralick M, Macdonald EM, Gomes T , et al; Canadian Drug Safety and Effectiveness Research Network. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014; 349: g6196
• 107 Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. Arch Intern Med 2010; 170 (12) 1045-1049
• 108 Greenberg S, Reiser IW, Chou SY, Porush JG. Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993; 119 (4) 291-295
• 109 Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1996; 124 (3) 316-320
• 110 Hughes WT, Feldman S, Chaudhary SC, Ossi MJ, Cox F, Sanyal SK. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978; 92 (2) 285-291
• 111 Joos B, Blaser J, Opravil M, Chave JP, Lüthy R. Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1995; 39 (12) 2661-2666
• 112 Kroll CR, Gettes LS. T wave alternans and Torsades de Pointes after the use of intravenous pentamidine. J Cardiovasc Electrophysiol 2002; 13 (9) 936-938
• 113 Black JR, Feinberg J, Murphy RL, Fass RJ, Carey J, Sattler FR. Clindamycin and primaquine as primary treatment for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS. Eur J Clin Microbiol Infect Dis 1991; 10 (3) 204-207
• 114 Toma E, Thorne A, Singer J , et al; CTN-PCP Study Group. Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). Clin Infect Dis 1998; 27 (3) 524-530
• 115 Toma E, Fournier S, Dumont M, Bolduc P, Deschamps H. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin Infect Dis 1993; 17 (2) 178-184
• 116 Smego Jr RA, Nagar S, Maloba B, Popara M. A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001; 161 (12) 1529-1533
• 117 Hughes W, Leoung G, Kramer F , et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993; 328 (21) 1521-1527
• 118 Rosenberg DM, McCarthy W, Slavinsky J , et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 2001; 15 (2) 211-214
• 119 Dohn MN, Weinberg WG, Torres RA , et al; Atovaquone Study Group. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1994; 121 (3) 174-180
• 120 Safrin S, Sattler FR, Lee BL , et al. Dapsone as a single agent is suboptimal therapy for Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1991; 4 (3) 244-249
• 121 Sun P, Tong Z. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats. Med Mycol 2014; 52 (8) 798-803
• 122 Ceballos ME, Ortega M, Andresen M, Wozniak A, García P, Balcells ME. Successful treatment with echinocandin in an HIV-infected individual failing first-line therapy for Pneumocystis jirovecii pneumonia. AIDS 2011; 25 (17) 2192-2193
• 123 Yao Z, Hua Z, Jun X, Chan W, Xiao-jun M. Lack of response in severe pneumocystis pneumonia to combined caspofungin and clindamycin treatment: a case report. Chin Med Sci J 2011; 26 (4) 246-248
• 124 Armstrong-James D, Stebbing J, John L , et al. A trial of caspofungin salvage treatment in PCP pneumonia. Thorax 2011; 66 (6) 537-538
• 125 Bozzette SA, Sattler FR, Chiu J , et al; California Collaborative Treatment Group. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323 (21) 1451-1457
• 126 Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey OW, La Voie L. Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med 1990; 323 (21) 1444-1450
• 127 Montaner JS, Guillemi S, Quieffin J , et al. Oral corticosteroids in patients with mild Pneumocystis carinii pneumonia and the acquired immune deficiency syndrome (AIDS). Tuber Lung Dis 1993; 74 (3) 173-179
• 128 The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990; 323 (21) 1500-1504
• 129 Briel M, Boscacci R, Furrer H, Bucher HC. Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infect Dis 2005; 5: 101
• 130 French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18 (12) 1615-1627
• 131 Mok HP, Hart E, Venkatesan P. Early development of immune reconstitution inflammatory syndrome related to Pneumocystis pneumonia after antiretroviral therapy. Int J STD AIDS 2014; 25 (5) 373-377
• 132 Shelburne III SA, Hamill RJ, Rodriguez-Barradas MC , et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81 (3) 213-227
• 133 Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002; 3 (3) 207-211
• 134 Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002; 35 (4) 491-493
• 135 Jagannathan P, Davis E, Jacobson M, Huang L. Life-threatening immune reconstitution inflammatory syndrome after Pneumocystis pneumonia: a cautionary case series. AIDS 2009; 23 (13) 1794-1796
• 136 Wislez M, Bergot E, Antoine M , et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164 (5) 847-851
• 137 Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). Indian J Med Res 2011; 134 (6) 866-877
• 138 Calligaro G, Meintjes G, Mendelson M. Pulmonary manifestations of the immune reconstitution inflammatory syndrome. Curr Opin Pulm Med 2011; 17 (3) 180-188
• 139 Sovaila S, de Raigniac A, Picard C , et al. Acute microbiologically negative hypoxic interstitial pneumonia on HAART: immune reconstitution inflammatory syndrome unmasking Pneumocystis jiroveci infection with an atypical presentation. J Med Life 2012; 5 (2) 189-191
• 140 Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK , et al; The Dutch AIDS Treatment Group. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327 (26) 1836-1841
• 141 Mallolas J, Zamora L, Gatell JM , et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. AIDS 1993; 7 (1) 59-64
• 142 DiRienzo AG, van Der Horst C, Finkelstein DM, Frame P, Bozzette SA, Tashima KT. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses 2002; 18 (2) 89-94
• 143 Hardy WD, Feinberg J, Finkelstein DM , et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. N Engl J Med 1992; 327 (26) 1842-1848
• 144 Bozzette SA, Finkelstein DM, Spector SA , et al; NIAID AIDS Clinical Trials Group. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995; 332 (11) 693-699
• 145 Hughes WT. Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998; 27 (1) 191-204
• 146 Girard PM, Landman R, Gaudebout C , et al; The PRIO Study Group. Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993; 328 (21) 1514-1520
• 147 El-Sadr WM, Murphy RL, Yurik TM , et al; Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998; 339 (26) 1889-1895
• 148 Barber BA, Pegram PS, High KP. Clindamycin/primaquine as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1996; 23 (4) 718-722
• 149 Yangco BG, Von Bargen JC, Moorman AC, Holmberg SD ; HIV Outpatient Study (HOPS) Investigators. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. Ann Intern Med 2000; 132 (3) 201-205
• 150 Lopez Bernaldo de Quiros JC, Miro JM, Peña JM , et al; Grupo de Estudio del SIDA 04/98. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98. N Engl J Med 2001; 344 (3) 159-167
• 151 Kazanjian PH, Fisk D, Armstrong W , et al. Increase in prevalence of Pneumocystis carinii mutations in patients with AIDS and P. carinii pneumonia, in the United States and China. J Infect Dis 2004; 189 (9) 1684-1687
• 152 Kazanjian P, Armstrong W, Hossler PA , et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000; 182 (2) 551-557
• 153 Stein CR, Poole C, Kazanjian P, Meshnick SR. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 2004; 10 (10) 1760-1765
• 154 Ma L, Kovacs JA, Cargnel A, Valerio A, Fantoni G, Atzori C. Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. J Infect Dis 2002; 185 (10) 1530-1532
• 155 Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999; 354 (9187) 1347-1351
• 156 Crothers K, Beard CB, Turner J , et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 2005; 19 (8) 801-805
• 157 Visconti E, Ortona E, Mencarini P , et al. Mutations in dihydropteroate synthase gene of Pneumocystis carinii in HIV patients with Pneumocystis carinii pneumonia. Int J Antimicrob Agents 2001; 18 (6) 547-551
• 158 Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthase gene. Lancet 1998; 351 (9116) 1631-1632
• 159 Walker DJ, Wakefield AE, Dohn MN , et al. Sequence polymorphisms in the Pneumocystis carinii cytochrome b gene and their association with atovaquone prophylaxis failure. J Infect Dis 1998; 178 (6) 1767-1775